desinr-gal said:
The article quoted seems to warn about the TB and BPC, not the GHK.
"When solution first contacts the membrane, it can cause a local pH drift of ±0.2–0.4 units — sufficient to denature or partially unfold sensitive peptides such as BPC-157 or TB-500."
OK so let’s reason on this with what we find with a quick scholarly article search. Instead of making assumptions on how far down the rabbit hole my search has gone. Now I’m not a chemist or scientist or even a holiday inn express guest. But we have some of the most complete online scholarly source libraries and the most powerful search tools we’ve ever had access to.
1) BP-157 is not a sensitive peptide, it is widely described in literature as a stable gastric pentadecapeptide because it is native to gastric digestive juices. If BPC-157 can withstand hours in an environment that is several pH units lower than a neutral buffer, it is highly improbable that a localized, temporary drift of a mere 0.2 to 0.4 units in a buffered preparation would be sufficient to cause denaturation or unfolding. (Seiwerth, S., et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology, 12, 627533; Sikiric, P., et al. (2014). The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Molecules, 17(4), 461–481)
2) TB-500 is typically used as the synthetic fragment Ac-LKKTETQ, consisting of only four to seven amino acids. Denaturation and unfolding refer to the disruption of complex structures, which are characteristic of large proteins. Small fragments like TB-500 lack the intricate three-dimensional folds that would be susceptible to denaturation by a minor pH change. TB4 is however fairly unstable from what I’ve read and this is why almost all research is done with the fragment TB500. (Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential-Simone Espositoa, Koen Deventera, Jan Goemanb, Johan Van der Eyckenb, Peter Van Eenooa)
3) The premise that a pH drift will occur and damage the product is typically nullified by standard pharmaceutical preparation practices, which require the use of proper buffers. The pH drift from filtration is transitory and happens briefly as the media is wetted. Now, normally in high quality pharma peptides they use a buffered solution to handle exactly this type of drift… we are probably not getting that type of product. TFA used to purify the petite may add to the pH problem. (Guideline on the Development and Manufacture of Synthetic Peptides. European Medicines Agency (EMA), Draft Guideline) However, as described in the literature above BPC-157 and TB500 have low susceptibility to denaturing even without a buffer.
4) Not having considered that the material I’ve read is likely referencing higher quality buffered peptides, I revisited the susceptibility of unbuffered GHK-Cu and KPV to filtration and pH drift. GHK-Cu is
stable at pH 4 to 7.5, but dissociation occurs at pH below 4, so testing pH prior to filtration could show you if you have room for the drift without damaging it. Apparently any TFA residual could cause the reconstituted solution to have a very low pH (GLOW/KLOW burn anyone?) which means it could be damaged even before filtering. KPV also a small peptide so now worries about denaturing, but attains a positive charge at pH below 7 so if the filter media has a negative charge it could selectively increase loss due to absorption. (
https://www.researchgate.net/figure...ys-Pro-diketopiperazine-formed_fig4_266679185 ; https://pmc.ncbi.nlm.nih.gov/articles/PMC5498804/ ) I guess it seems reasonable to conclude that filter would negatively impact KPV and GHK-Cu. GHK-Cu in an unbuffered lyophilized powder with TFA residuals is already damaged if the reconned solution pH is below 4.
Again I not an expert by any means, but I can research read and reason ok. Those are my findings so far.